Cite
HARVARD Citation
Faivre-Finn, C. et al. (n.d.). Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet oncology. 18 (8), pp. 1116-1125. [Online].